Halozyme Therapeutics Inc [HALO] stock is trading at $62.9, up 1.29%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HALO shares have gain 6.57% over the last week, with a monthly amount glided 9.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Halozyme Therapeutics Inc [NASDAQ: HALO] stock has seen the most recent analyst activity on August 06, 2025, when Morgan Stanley upgraded its rating to a Overweight but kept the price target unchanged to $75 for it. On May 14, 2025, downgrade downgraded it’s rating to Equal-Weight but maintained its price target of $62 on the stock. Leerink Partners downgraded its rating to a Underperform but stick to its price target of $47 on May 13, 2025. Wells Fargo downgraded its rating to a Equal Weight and raised its price target to $62 on October 07, 2024. JP Morgan downgraded its rating to Neutral for this stock on September 19, 2024, and upped its price target to $57. In a note dated June 07, 2024, Piper Sandler downgraded an Neutral rating on this stock and boosted its target price from $48 to $51.
Halozyme Therapeutics Inc [HALO] stock has fluctuated between $42.01 and $70.50 over the past year. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $62.9 at the most recent close of the market. An investor can expect a potential drop of -1.43% based on the average HALO price forecast.
Analyzing the HALO fundamentals
Halozyme Therapeutics Inc [NASDAQ:HALO] reported sales of 1.18B for the trailing twelve months, which represents a growth of 40.79%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.58%, Pretax Profit Margin comes in at 0.59%, and Net Profit Margin reading is 0.47%. To continue investigating profitability, this company’s Return on Assets is posted at 0.27, Equity is 1.37 and Total Capital is 0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 4.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Halozyme Therapeutics Inc’s Current Ratio is 8.36. As well, the Quick Ratio is 7.01, while the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 6.24, the price to book ratio is 22.23 and price to earnings (TTM) ratio is 14.37.
Transactions by insiders
Recent insider trading involved Torley Helen, PRESIDENT AND CEO, that happened on Jul 10 ’25 when 20000.0 shares were sold. PRESIDENT AND CEO, Torley Helen completed a deal on Jul 09 ’25 to sell 20000.0 shares. Meanwhile, PRESIDENT AND CEO Torley Helen sold 20000.0 shares on Jul 08 ’25.
